RODENT AND MONKEY TESTING FOR NIDA MEDICATION DISCOVERY PROGRAMS Release Date: August 8, 2002 NOTICE: NOT-DA-03-021 RFP AVAILABLE: N01DA-3-8823 National Institute on Drug Abuse (NIDA) The National Institute of Drug Abuse (NIDA) is soliciting proposals from qualified organizations having in-house capability to perform in vivo rodent and primate pharmacology studies of potential pharmacotherapies for drug dependence disorders. The primary emphasis is on testing conducted for NIDA's Opiod Treatment Discovery program. The objectives of this requirement are: (1) to determine the in vivo receptor activity of novel compounds; (2) to determine the effects of compounds in opiate- dependent animals, primarily during opiate withdrawal; (3) to evaluate compounds for their potential suitability for clinical trials as relapse prevention agents; and (4) to identify and acquire standard compounds which merit the aforementioned types of evaluation. In addition, this contract shall support follow-up rodent and/or rodent and/or primate pharmacology studies of compounds identified as promising potential drug dependence treatment agents. This requirement is a follow-on procurement to contract number N01DA-8- 8088 with Virginia Commonwealth University. The contract work will require the contractor to perform blind tests on the identity of proprietary test compounds, and evaluate the compounds in established assays. The NIDA Medications Development Division will utilize the resulting data. In order to handle substances under the Controlled Substances Act of 1970, the successful offeror must indicate possession of a current DEA registration for Schedule II-V substances prior to award, and must demonstrate the ability to obtain DEA registration for Schedule I controlled substances. NIDA anticipates that a 5-year incrementally funded completion-type contract with options for additional supplies and labor hours will result from this procurement. RFP No. N01DA-3-8823 will be available electronically about August 14, 2002 and interested sources may access it through the Internet at: www.fedbizopps.gov or through the NIDA website address: www.nida.nih.gov/RFP/RFPList.html. NIDA will issue a streamlined RFP for this acquisition to include only the Work Statement, Deliverables and Reporting Requirements, Special Requirements and Mandatory Qualifications, Technical Evaluation Criteria, and other necessary Proposal Preparation Instructions. Proposals will be due about October 7, 2002. Following proposal submission and the initial review process, the Contracting Officer may require additional documentation from offerors in the competitive range. This advertisement does not commit the Government to award a contract. Point of Contact: Diane M. Loeb Contract Specialist National Institute on Drug Abuse Contracts Management Branch, OPRM 6001 Executive Boulevard Room 3105, MSC 9543 Bethesda, Maryland 20892-9543 Electronic Mail Address: dl294p@nih.gov Telephone: (301) 443-6677 Fax: (301) 443-7595
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |